Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Sponsor: Pardis Noor Medical Imaging and Cancer Center
Summary
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.
Official title: An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-06-01
Completion Date
2026-04-30
Last Updated
2025-11-25
Healthy Volunteers
No
Conditions
Interventions
Bevacizumab
Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.
Locations (1)
Pardis Noor Medical Imaging and Cancer Center
Tehran, Tehran Province, Iran